WINNIPEG, MB, Jan. 18, 2021 /CNW/ - Waverley Pharma Inc. (TSXV:
WAVE) ("Waverley Pharma" or the "Company"), an emerging
Canadian pharmaceutical company, is pleased to announce that its
wholly owned Irish subsidiary, Waverley Pharma Europe Limited
("WPEL"), has been awarded exclusive distribution rights for
capecitabine by the National Health Services of Scotland ("NHS Scotland").
The awarded NHS Scotland tender is projected to increase the
Company's revenue by approximately £200,000 on an annual basis.
This opportunity also represents WPEL's first successful tender
proposal for capecitabine in the NHS Scotland region. The tender
will commence on February 1, 2021 and
has a duration of two years. WPEL currently has awarded tenders for
capecitabine in both Wales and
England with each region's
respective National Health Services organization.
"Waverley Pharma is excited to announce our fifth successful
tender award since 2019, which affirms our commitment to expanding
our oncology presence in the UK and EU markets," stated
Larry Thiessen, President and Chief
Executive Officer.
About Waverley Pharma
Waverley Pharma is an emerging pharmaceutical company focused on
the development and commercialization of safe, effective, and
affordable cancer therapeutics in the EU, United Kingdom and North American markets. The
Company, through its subsidiary, is currently selling three generic
oncology products in the United
Kingdom, namely capecitabine, temozolomide and erlotinib. In
addition, the Company is developing two generic oncology products
in Europe, namely pemetrexed and
bortezomib and additional products in the
United States. Waverley Pharma is committed to providing
patients with affordable prescription medicines that lower
healthcare costs and provide a better quality of life. For more
information on Waverley Pharma please visit
www.waverleypharma.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Forward Looking Information: Statements
contained in this press release that are not statements of
historical fact, including, without limitation, statements
containing the words "believes", "may", "plans", "will",
"estimates", "continues", "anticipates", "intends", "expects" and
similar expressions, may constitute "forward-looking information"
within the meaning of applicable Canadian and U.S. federal
securities laws (such forward-looking information and
forward-looking statements are hereinafter collectively referred to
as "forward-looking statements"). Forward-looking statements
include tender awards and other estimates, analysis and opinions of
management of the Company made in light of its experience and its
perception of trends, current conditions and expected developments,
as well as other factors which the Company believes to be relevant
and reasonable in the circumstances. Inherent in forward-looking
statements are known and unknown risks, uncertainties and other
factors beyond the Company's ability to predict or control that may
cause the actual results, events or developments to be materially
different from any future results, events or developments expressed
or implied by such forward-looking statements, and as such, readers
are cautioned not to place undue reliance on forward-looking
statements. Such risk factors include, among others, the Company's
potential product revenues, stage of development, additional
capital requirements, risks associated with obtaining regulatory
approval to market the Company's products, the ability to protect
its intellectual property, dependence upon collaborative partners,
changes in government regulation or regulatory approval processes,
and rapid technological change in the industry. Such statements are
based on a number of assumptions which may prove to be incorrect,
including, but not limited to, assumptions about: general business
and economic conditions; the impact of changes in Canadian-US
dollar and other foreign exchange rates on the Company's revenues,
costs and results; the timing of the receipt of regulatory and
governmental approvals for the Company's research and development
projects; the availability of financing for the Company's
commercial operations and/or research and development projects, or
the availability of financing on reasonable terms; the
uncertainties associated with the acceptance and demand for new
products and market competition. The foregoing list of important
factors and assumptions is not exhaustive. The Company undertakes
no obligation to update publicly or otherwise revise any
forward-looking statements or the foregoing list of factors, other
than as may be required by applicable legislation. Additional
discussion regarding the risks and uncertainties relating to the
Company and its business can be found in the Company's other
filings with the applicable Canadian securities regulatory
authorities.
SOURCE Waverley Pharma Inc.
